|
|
Article: Preliminary Results of Muscular Dystrophy Clinical Trial Encouraging
- Article from:
- U.S. Newswire
- Article date:
- October 21, 2006
CopyrightCopyright 2006 U.S. Newswire. Provided by ProQuest LLC. (Hide copyright information)
|
To: National Desk, Health Reporter
Contact: Bob Mackle of the Muscular Dystrophy Association, 520-
529-5317; 520-4665-3076 (cell) or bobmackle@mdausa.org
TUCSON, Ariz., Oct. 21 /U.S. Newswire/ -- An experimental compound
developed by PTC Therapeutics of South Plainfield, N.J., with support
from the Muscular Dystrophy Association (MDA), has shown promise as a
treatment for Duchenne muscular dystrophy (DMD) in a clinical trial
of boys with the disease, the Association announced today.
"We're really encouraged by these exciting results," said
neurologist Valerie Cwik, MDA vice president - research and medical
director. "We're very gratified to see MDA's support of PTC124
development translated ...